Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central anxious process, conolidine modulates alternate molecular targets. A Science Advances review discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://howardx149qhd5.dreamyblogs.com/profile